A single-dose, dose-escalation study of subcutaneous daclizumab high-yield process in healthy volunteers.

Trial Profile

A single-dose, dose-escalation study of subcutaneous daclizumab high-yield process in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2016

At a glance

  • Drugs Daclizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics; Pharmacokinetics
  • Acronyms 1015
  • Most Recent Events

    • 01 Oct 2014 Results of integrated analysis intravenous and subcutaneous, single- and multiple- dose administration using patient data from CTPs 289783, 289782 and 289780 published in the Clinical Pharmacokinetics
    • 01 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top